Zhejiang Meida Industrial (002677.SZ): Planning company ownership change, continues suspension of trading.
Zhejiang Meida (002677.SZ) announced that the company's controlling shareholder and actual controller, Xia Zhisheng and Xia Ding, are planning for changes in control rights, which may result in a change in the company's actual controller. The company's stock has been suspended from trading since July 10, 2026 (Friday).
Zhejiang Meida Industrial (002677.SZ) announced that the company's controlling shareholder and actual controller Xia Zhisheng and Xia Ding are planning to change the controlling rights, which may result in a change of the company's actual controller. The company's stock has been suspended from trading since July 10, 2026 (Friday).
On July 13, 2026, the company received a notice from the controlling shareholder and actual controller Xia Zhisheng and Xia Ding, stating that all parties are actively advancing the various work related to this transaction. The overall plan is still under negotiation, and the parties have not yet signed a formal agreement. The company expects that trading will not resume on July 14, 2026 (Tuesday). The company's stock will continue to be suspended from trading starting on July 14, 2026 (Tuesday), with the suspension expected to last for no more than 3 trading days.
Related Articles

HK Stock Market Move | Estun Automation's stock (02715) surged over 9% after the announcement. It is expected that the company's net profit attributable to shareholders in the first half of the year will be between 1.5 billion and 1.8 billion yuan.

HK Stock Market Move | INNOVENT BIO (01801) rose more than 3% and reached an exclusive licensing agreement with Spero for IBI355. The clinical phase II study for treating SjD will begin early next year.

"A-share opening express | ChiNext Index rose by 0.74% Cultivate diamond, storage chips, semiconductor, optical fiber and other sectors showing active performance"
HK Stock Market Move | Estun Automation's stock (02715) surged over 9% after the announcement. It is expected that the company's net profit attributable to shareholders in the first half of the year will be between 1.5 billion and 1.8 billion yuan.

HK Stock Market Move | INNOVENT BIO (01801) rose more than 3% and reached an exclusive licensing agreement with Spero for IBI355. The clinical phase II study for treating SjD will begin early next year.

"A-share opening express | ChiNext Index rose by 0.74% Cultivate diamond, storage chips, semiconductor, optical fiber and other sectors showing active performance"

RECOMMEND





